A B S T R A C T
The current therapeutic strategy for the treatment of chronic kidney diseases only ameliorates disease progression. During renal injury, developmental genes are re-expressed and could be potential therapeutic targets. Among those genes reactivated in the adult damaged kidney, Gremlin is of particular relevance since recent data suggest that it could be a mediator of diabetic nephropathy and other progressive renal diseases. Earlier studies have shown that Gremlin is upregulated in transdifferentiated renal proximal tubular cells and in several chronic kidney diseases associated with fibrosis. However, not much was known about the mechanisms by which Gremlin acts in renal pathophysiology. The role of Gremlin as a bone morphogenetic protein antagonist has clearly been demonstrated in organogenesis and in fibrotic-related disorders. Gremlin binds to vascular endothelial growth factor receptor 2 (VEGFR2) in endothelial and tubular epithelial cells. Activation of the Gremlin-VEGFR2 axis was found in several human nephropathies. We have recently described that Gremlin activates the VEGFR2 signaling pathway in the kidney, eliciting a downstream mechanism linked to renal inflammatory response. Gremlin deletion improves experimental renal damage, diminishing fibrosis. Overall, the available data identify the Gremlin-VEGFR2 axis as a novel therapeutic target for kidney inflammation and fibrosis and provide a rationale for unveiling new concepts to investigate in several clinical conditions. Keywords: diabetic nephropathy, fibrosis, Gremlin, inflammation, TGF-b1, VEGF V C The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
I N T R O D U C T I O N
Gremlin (GREM1) is a developmental gene that regulates morphogenesis, and its role in embryogenesis has clearly been demonstrated in limb development, neural crest differentiation and metanephric kidney organogenesis [1] [2] [3] . Gremlin knockout mice die of renal aplasia, lung defects and limb malformations. A small number of these mice are viable, with a single, enlarged left kidney and grossly normal histology [3] . In adult tissues, Gremlin becomes quiescent and it is not expressed in heart, kidney, liver or skeletal muscle [2] , while high levels can be found in brain, ovary, intestine and colon tissue [4] . In contrast, Gremlin induction has been described in injured tissues [5] . More importantly, Gremlin has been involved in a wide array of pathological conditions, such as angiogenesis; cancer; osteogenesis; liver, lung and renal fibrosis and diabetes [5] . Although broad actions of Gremlin have been described in different systems and diseases, this review is mainly focused on the role of Gremlin as a mediator of renal injury.
S T R U C T U R E O F G R E M L I N A N D I N T E R A C T I O N W I T H B O N E M O R P H O G E N E T I C P R O T E I N S ( B M P s )
Gremlin was initially identified in cultured mesangial cells exposed to high glucose and therefore was initially known as induced in high glucose-2 (IHG-2) [6] . Gremlin is a member of the DAN family of secreted BMP antagonists and belongs to the cysteine knot superfamily protein [1, 7, 8] . Gremlin (accession numbers: nucleotide NM_013372, protein NP_037504.1) is a highly conserved 184 amino acid protein (20.7 kDa). The human Gremlin gene (GREM1) has been mapped to chromosome 15q13-q15 [4] . This glycosylated protein contains a cysteine-rich region and a cysteine knot motif responsible for BMP binding, whose structure is shared by members of the transforming growth factor beta (TGF-b) superfamily [7] . Analysis of the predicted amino acid sequence indicated the presence of several significant features, including potential nuclear localization signals near the C-terminal, potential N-linked glycosylation sites and multiple potential sites for phosphorylation [2] . The signaling peptide and a predicted glycosylation site have been identified, but there are no solid data about nuclear localization (Figure 1a) . Earlier studies showed that Gremlin exists in monomeric form and in a covalent homodimer form [9] . This protein can be secreted or in cell-associated forms; the latter can be found in the external surface of expressing cells, as well as within the endoplasmic reticulum and the Golgi [6] . Most of the known Gremlin responses are extracellular [1, 7, 8] , but intracellular actions have also been described [10] .
GREMLIN ACTS AS A BMP ANTAGONIST
BMPs are secreted extracellular matrix-associated proteins that regulate a wide range of developmental processes, including limb and kidney formation. A critical element of BMP regulation is the presence of secreted antagonists, such as Gremlin [11] . Gremlin acts as a BMP antagonist by forming heterodimers with BMP-2, -4 and -7, preventing their interactions with specific receptors, and subsequent downstream signaling pathway activation involving the Smad 1/5/8 proteins [1, 3, 11] . It should be noted that a counterbalance of BMP and TGF-b signaling exists in many physiological processes and Gremlin is another player in these contexts. Using kidney epithelial cells as a model, a group from Brazil has recently shown that Gremlin has a low affinity for BMP-7 and preferentially binds to BMP-2 [12] . Additionally, Gremlin can also specifically bind to BMP-4 precursor protein inside the cells. Besides acting as a BMP antagonist, Gremlin can exert BMP independent mechanisms, including tumor cell proliferation, endothelial cell migration, fibrosis and intracellular signaling activation [2, 8, 11, 13] .
Gremlin shares a structural cysteine knot motif with vascular endothelial growth factor (VEGF) and with TGF-b [14] . Using surface plasmon resonance analysis, it was found that Gremlin is a novel ligand of VEGFR2 [14] . VEGFR2 is a main VEGF receptor on endothelial cells [15] and VEGF is a crucial regulator of vascular development during embryogenesis as well as blood vessel formation in adults [15] . In endothelial cells, Gremlin binds to VEGFR2, in a BMP-independent manner, inducing its tyrosine phosphorylation and downstream activation, resulting in cell proliferation, migration and formation of angiogenic sprouts [15] . Several studies have clearly shown that the Gremlin-VEGFR2 axis is closely linked to angiogenesis in both physiological and pathological processes [14] .
Several downstream mechanisms of the Gremlin-VEGFR2 pathway have been described, including activation of transcription factors. In endothelial cells, cyclic adenosine monophosphate response element-binding protein activation mediates the early phases of the angiogenic response to Gremlin, including stimulation of endothelial cell motility and permeability [16] . In the kidney, nuclear factor (NF)-jB activation is an early key signaling pathway involved in Gremlinmediated inflammation [17] .
In skin keratinocytes and fibroblasts, Gremlin activation of VEGFR2 is linked to NF-E2-related factor 2 (Nrf2) signaling and subsequent skin cell protection [18] . However, in cancer cell lines, Gremlin causes cell migration, invasion and proliferation through BMP-and VEGFR2-independent mechanisms, suggesting that other receptors could be involved in Gremlinmediated oncogene response [19] . Moreover, a recent study has described that monomeric Gremlin acts as a VEGFR2 antagonist and retains its BMP-antagonist activity [9] . Interestingly, although binding of heparin or polysaccharide heparan sulphate is necessary for VEGFR2 activation by Gremlin, this does not appear to be essential for Gremlinmediated BMP antagonism [20] . All these data indicate the complex Gremlin actions (Figure 1b) , showing that more research is needed.
VEGFR2 is a potential Gremlin receptor in the kidney
As described in endothelial cells, we also found that in cultured human tubular epithelial cells, Gremlin binds to VEGFR2 and activates this pathway by a BMP-independent process, as shown by the lack of BMP-2, -4 and -7 effects on Gremlininduced VEGFR2 phosphorylation [17] . Using a mouse model of Gremlin-induced renal damage, we found the presence of Gremlin-binding sites in proximal tubular epithelial cells that co-localized to active VEGFR2 [17] . These data have been confirmed recently, showing that Gremlin is able to bind broadly across the various regions of kidney in a heparan sulfatedependent manner, with particularly intense binding to tubular structures in the renal cortex [20] . Moreover, VEGFR2 signaling pathway activation by Gremlin was linked to the regulation of renal inflammation by activation of the NF-kB pathway, showing that VEGFR2 is a functional receptor in the kidney [17] . In several human renal diseases, Gremlin overexpression was associated with VEGFR2 activation, mainly in the tubulointerstitium [17] , suggesting that the Gremlin-VEGFR2 axis could contribute to renal damage progression. Interestingly, some reports suggest that podocytes do not express VEGFR2 [21] , showing the importance of searching for additional Gremlin receptors in the kidney.
VEGF/VEGFR2 versus Gremlin/VEGFR2 in renal diseases
Despite the large number of studies conducted to determine the potential involvement of VEGF and its receptors in the pathogenesis of renal damage, the exact role of this molecule is still not well understood. Experimental studies of VEGFA inhibition have generated conflicting results [22] . In spite of the fact that animal models may not correctly reproduce human diabetic nephropathy, this controversy could be also due to the large variability observed in human studies [23] . Indeed, different groups have shown that VEGFA is generally upregulated in the kidneys of diabetic rodents and in renal biopsies and plasma from patients with type 1 or 2 diabetes, leading to the hypothesis that the increased level of VEGFA in diabetes is detrimental to glomerular function. Moreover, different groups have succeeded in showing that inducing VEGF expression in normal adult mice can reproduce features of diabetic renal disease. Conditional podocyte-specific VEGF-overexpressing mice presented with albuminuria, thickened glomerular base membrane, foot process effacement and mesangial expansion [24] . Importantly, in human diabetic nephropathy, we have noted that Gremlin overexpression and VEGFR2 activation are located in tubulointerstitial cells [17] , clearly showing a different spatial distribution of VEGFA and Gremlin expression pattern, and probably functional consequences.
G R E M L I N A N D I N F L A M M A T I O N
The role of Gremlin in the inflammatory response has been poorly studied. A first in vitro study described Gremlin as an inhibitor for monocyte chemotaxis, while a subsequent study in monocytes/macrophages showed that Gremlin binds to macrophage migration inhibitory factor (MIF) and acts as an endogenous MIF antagonist to regulate monocyte migration [25] . The relation of Gremlin and monocytes in vivo is controversial. In a model of experimental atherosclerosis in ApoE knockout mice, Gremlin administration reduced macrophage content in atherosclerotic plaque by inhibiting MIF and attenuated progression of the atheroma lesion [25] . These data suggest that Gremlin1 is an endogenous antagonist of MIF and therefore could influence plaque vulnerability. In patients with coronary artery disease, the serum Gremlin1:MIF ratio indicates acuity of the disease and the degree of plaque stability [26] . Recently, platelets have been identified as a novel source of Gremlin, and there is some evidence suggesting that Gremlin might act as a thrombo-inflammatory mediator in cardiovascular diseases [27] .
Several in vitro studies in endothelial and tubuloepithelial cells have found that Gremlin stimulates the expression of several chemokines and adhesion molecules via VEGFR2 [16, 17] . Interestingly, in human glomerulonephritis, Gremlin induction was found in infiltrating immune cells [28] . Recent evidence described by our group suggests that Gremlin via the VEGFR2 pathway could contribute to renal inflammation. In mice, kidney administration of recombinant Gremlin induced an early inflammatory response, characterized by overexpression of pro-inflammatory factors (chemokines, adhesion molecules and cytokines) and renal infiltration of monocytes/macrophages and lymphocytes [17] . Moreover, transgenic mice overexpressing GREM1 specifically in tubular cells presented increased susceptibility to renal damage associated with upregulation of pro-inflammatory factors such as monocyte chemoattractant protein-1 [29, 30] . In addition, in the experimental model of unilateral ureteral obstruction in mice, pharmacological blockade of VEGFR2 using a VEGFR kinase inhibitor, decreased renal induction of Gremlin as well as inflammation [17] .
G R E M L I N A N D R E N A L F I B R O S I S
Multiple evidence suggests that Gremlin could be an important promoter of fibrosis in different settings, including renal, liver, lung and heart [5, 31, 32] . More recently, chronic pancreatitis can now be added to the growing list of fibrotic disorders in which Gremlin is implicated [33] . The receptor involved in Gremlin fibrotic responses, including the kidney, has not been described, and BMP antagonism seems to be involved in limited settings. These data suggest that further studies on this molecule at different stages of fibrosis and in the different organs involved are required.
Renal fibrosis is the final common pathway in progressive renal disease, and it remains an unresolved challenge. Irrespective of the underlying cause, chronic kidney disease is linked to the development of tubulointerstitial fibrosis, characterized by the accumulation of extracellular matrix. The key cellular player of fibrosis is the myofibroblast. There are different sources of myofibroblasts, including activation of tissue fibroblasts, migration of circulating mesenchymal progenitors or cell transitions, including epithelial mesenchymal transition (EMT) or endothelial mesenchymal transition [34, 35] . We have demonstrated that in murine renal fibroblasts, stimulation with recombinant Gremlin upregulated profibrotic genes, such as TGF-b, and augmented the production of matrix proteins, including type I collagen. The blockade of endogenous Gremlin with small interfering RNA inhibited TGF-b-induced extracellular matrix proteins upregulation [36] , suggesting that Gremlin is a downstream mediator of TGF-b profibrotic effects.
Gremlin is induced in experimental and human kidney diseases associated with fibrosis. A recent study using tubular epithelial-specific targeted deletion of Gremlin in mice has described an attenuated fibrotic gene response compared with wild-type controls in the recovery phase of the folic acid model [3] , although the receptor involved has not been evaluated. As noted, abundant Gremlin expression was observed in human diabetic nephropathy, mainly in areas of tubulointerstitial fibrosis [31] , in the tubulointerstitium of chronic allograft nephropathy [37] and in glomerular crescents of human pauci-immune glomerulonephritis [28] (Figure 2 ). In addition, we recently detected that urinary Gremlin levels were markedly upregulated in pauci-immune crescentic glomerulonephritis patients compared with non-vasculitic crescentic glomerulonephritis, healthy donors and in patients with other renal diseases and correlated with the percentage of crescents, tubulointerstitial fibrosis and serum creatinine. Moreover, we confirm a strong expression of Gremlin protein and mRNA in cellular glomerular crescents and this expression was co-localized with CD163 and CCL18, both induced and expressed in activated macrophages. These results propose Gremlin as a non-invasive biomarker in this glomerulonephritis (ASN Annual Meeting 2016).
EMT-related changes are an initial step in renal damage and an important potential therapeutic target. An earlier in vitro study showed Gremlin induction in tubular epithelial cells undergoing EMT [38] , suggesting that Gremlin could be involved in this process. We demonstrated that in cultured human tubular epithelial cells, transfection with a Gremlin expression vector or stimulation with recombinant Gremlin caused the loss of their epithelial properties, including the disappearance of epithelial proteins, such as E-cadherin and pan-cytokeratin, and induced a myofibroblast phenotype characterized by induction of the mesenchymal markers a-SMA and vimentin and the activation of enzymes involved in the degradation of the epithelial membrane, like metalloproteinase-9 [39] .
Also, EMT ( Figure 3 ) is a key event in the formation of metastases of malignant solid tumors, thus being involved in the invasive front of several cancer types. In different cancer cells, Gremlin regulates migration, invasion and proliferation, independent of BMP and VEGFR2 [14] . Future studies are needed to define the receptor involved in Gremlin responses in EMT and fibrotic and proliferative disorders.
In the kidney, TGF-b is activated in response to a variety of EMT inducers and regulates several transcription factors driving this process [39, 40] . In tubular epithelial cells, Gremlin increased TGF-b gene expression and protein synthesis. Endogenous TGF-b blockade by a neutralizing antibody markedly diminished Gremlin induction of EMT [39] . Additionally, TGF-b caused Gremlin production, and Gremlin gene silencing blocked TGF-b-induced EMT [39] . These data suggest that an autocrine loop Gremlin-TGF-b may contribute to sustained overproduction of both factors and therefore to the induction of a profibrotic environment in the kidney.
Among the signaling pathways involved in fibrosis and EMT regulation, the Smad pathway has special relevance. In tubular epithelial cells, Gremlin caused early activation of the Smad signaling pathway (Smad2/3 phosphorylation and nuclear translocation) in a direct and TGF-b-independent manner [39] . However, the long-term incubation of these cells with Gremlin increased TGF-b production and caused sustained Smad activation and a phenotype conversion into myofibroblast-like cells [39] . The Smad pathway blockade by Smad7 overexpression, which blocks Smad 2/3 activation, diminished EMT changes observed in Gremlin-transfected tubuloepithelial cells. All these data suggest that Gremlin could be a potential anti-fibrotic target for renal diseases. In podocytes, Gremlin also activates the Smad pathway [21] , although the receptor involved was not described. Moreover, we observed that the blockade of VEGFR2 using SU5416, a VEGFR2 kinase inhibitor, did not block Gremlininduced early Smad activation (unpublished data), suggesting that additional receptors should be involved in this process.
Of interest, tubule-specific GREM1 transgenic mice present a normal phenotype, without proteinuria and renal function involvement, for at least 6 months of follow-up [29] . However, in response to acute renal damage caused by folic acid nephrotoxicity, these transgenic mice presented increased proteinuria, tubular lesions, interstitial cell infiltration and mild fibrosis significantly more prominent than wild-type mice. Tubular human Gremlin overexpression was correlated with the renal upregulation of murine Gremlin, profibrotic factors, such as TGF-b and a-SMA, and increased infiltration of monocytes/ macrophages and lymphocytes [31] . Taken together, our results suggest that Gremlin-overexpressing mice have an increased susceptibility to renal damage, supporting the involvement of Gremlin in renal damage progression.
G R E M L I N A N D D I A B E T I C N E P H R O P A T H Y
Many studies, including ours, suggest that Gremlin participates in the pathogenesis of diabetic nephropathy. The first study of Brady et al. identified Gremlin as a gene induced in vitro when human mesangial cells were exposed to high extracellular glucose levels and upregulated in the renal cortex of streptozotocin-induced diabetic nephropathy rats [6] . More recently, in vitro studies showed that Gremlin causes podocyte injury, including changes in levels and nephrin/synaptopodin distribution [21] . Moreover, Gremlin expression was elevated in high glucose-treated podocytes and Gremlin silencing effectively attenuated high glucose-induced apoptosis [21] . Furthermore, in experimental models of diabetes, Gremlin blockade slowed the progression of the disease and reduced renal fibrosis. Knockout mice heterozygous for GREM1 exhibited renal protection in a streptozotocin-induced model of type 1 diabetes [41] . However, future studies using alternative Gremlin blockade strategies are still necessary to translate these promising results. As mentioned previously, in renal biopsy samples of human diabetic nephropathy patients, we detected Gremlin expression in podocytes, mesangial cells and parietal epithelial cells [31] . Moreover, we have shown that tubular overexpression of GREM1 in transgenic mice aggravates renal damage in streptozotocin-induced experimental diabetes by developing greater glomerular and tubulointerstitial injury [30] . These diabetic transgenic mice had significantly greater glomerular basement membrane thickening, increased mesangial matrix and podocytopenia when compared with diabetic wildtype mice [30] .
Besides a therapeutic target, Gremlin could also be a potential risk biomarker of diabetic nephropathy progression. There is an early observational study in a small group of patients with type 1 (20 cases) and type 2 diabetes mellitus (11 cases) that has found increased urinary Gremlin excretion in diabetic patients with nephropathy [42] .
Regarding the genetic component of type 2 diabetes, several risk alleles have been extensively explored in order to explain this common and polygenic disease and the microvascular complications. Even GREM1 genetic variants have been screened and the single nucleotide polymorphism rs1129456 located in the 3 0 -UTR region conferred an increased risk of developing diabetic nephropathy, with an odds ratio of 1.69, but still too low to assess diabetic patient risk. To date, TCF7L2 constitutes one of strongest genetic markers associated with type 2 diabetes, with a similar power to estimate disease risk. The combination of several alleles in large case-control studies seems to be more enlightening, demonstrating an $6-fold increased risk of developing diabetes in individuals carrying six risk alleles compared with those with no risk alleles [43] . It seems reasonable to consider the assessment of genetic risk in diabetic patients with diabetic nephropathy, including GREM1 and TCF7L2 risk alleles that are certainly biologically linked [44] in combination with other known risk alleles.
G R E M L I N A N D O T H E R C L I N I C A L S E T T I N G S
Elevated levels of Gremlin were found in the lungs of pulmonary arterial hypertension patients [45] , and its circulating levels were associated with patients' functional status and survival [46] . In a murine hypoxia/SU5416 model of pulmonary arterial hypertension, treatment with an anti-Gremlin antibody reduced pulmonary vascular remodeling and right ventricular hypertrophy [47] , suggesting that Gremlin could be a therapeutic target for this disease. Information on Gremlin in cardiovascular pathologies is scarce. In an early study we described overexpression of Gremlin in experimental and human vascular calcification [48] . However, the effect of Gremlin in vascular smooth muscle or cardiac cells has not been deeply investigated. Another important clinical condition where Gremlin can be involved is obesity. An early study showed that Gremlin is expressed in pre-adipocyte cell lines and modulated during adipogenesis. In bone marrow mesenchymal stem cells, miR-27a upregulation could inhibit adipogenesis and promote osteogenesis by directly targeting Gremlin [49] . Silencing Gremlin and/ or adding BMP-4 promoted the pre-adipocytes to assume an oxidative beige/brown adipose phenotype [50] , showing its role in hypertrophic obesity. All these data show the complexity of Gremlin and pointing to the importance of further research on this molecule and its receptors and molecular mechanisms.
C O N C L U S I O N S
Our understanding of the role of Gremlin in physiopathological conditions is evolving, with implications not only in matrix regulation but also in vascular homeostasis, as a VEGFR2 agonist, and in tumor biology, promoting cancer cell survival and expansion.
Gremlin is upregulated in a variety of renal diseases, mainly in crescentic glomerulonephritis and diabetic nephropathy and it has been reported to play a pro-fibrogenic role in the kidneys, lungs and liver through several mechanisms, including blockade of antifibrogenic BMP signaling and function. Thus, investigation of Gremlin-targeted therapies potentially could serve to treat renal and other diseases linked to inflammation and fibrosis. A very active field is also the manipulation of Gremlin to inhibit cancer cell growth and progression.
In summary, Gremlin may represent a novel target for stemming fibrotic disease progression in a number of clinical conditions, including renal diseases. 
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